Author:
Alarcon-Zapata Pedro,Perez Andy J.,Toledo-Oñate Karin,Contreras Hector,Ormazabal Valeska,Nova-Lamperti Estefania,Aguayo Claudio A.,Salomon Carlos,Zuniga Felipe A.
Subject
General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference74 articles.
1. Ovarian cancer relapse: from the latest scientific evidence to the best practice;Luvero;Crit. Rev. Oncol. Hematol.,2019
2. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J. Clin.,2021
3. Advances in tumour biomarkers for screening, diagnosis and management of ovarian malignancies;Kumar;J. Clin. Diagn. Res.,2018
4. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update;Berek;Int. J. Gynaecol. Obstet.,2021
5. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial;Lancet,2002
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献